KBC Group
DNTH icon

KBC Group’s Dianthus Therapeutics DNTH Stock Holding History

KBC Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96K Buy
+987
New +$86.2K ﹤0.01% 1443
2025
Q1 		– Sell
-1,593
Closed -$35K – 1882
2024
Q4 		$35K Buy
+1,593
New +$41K ﹤0.01% 1826

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

KBC Group's DNTH Position: Q2 2026 in Review

KBC Group opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 987 shares worth $96K. The stake represents ﹤0.01% of the portfolio and ranks #1443 among its holdings. This is a return to the name: KBC Group previously reported a position in DNTH as recently as Q4 2024.

KBC Group first reported a position in DNTH in Q4 2024 and has held it in 2 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • KBC Group held 987 shares of Dianthus Therapeutics worth $96K as of Q2 2026.
  • Dianthus Therapeutics was a new KBC Group position in Q2 2026.
  • Dianthus Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1443 holding.
  • KBC Group first reported a position in Dianthus Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.